Related references
Note: Only part of the references are listed.Proprotein Convertase Subtilisin/Kexin Type 9 Promotes Gastric Cancer Metastasis and Suppresses Apoptosis by Facilitating MAPK Signaling Pathway Through HSP70 Up-Regulation
Beili Xu et al.
FRONTIERS IN ONCOLOGY (2021)
Potentiating CD8+ T cell antitumor activity by inhibiting PCSK9 to promote LDLR-mediated TCR recycling and signaling
Juanjuan Yuan et al.
PROTEIN & CELL (2021)
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma
Shi-Zhe Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Small Interfering RNA Therapeutic Inclisiran: A New Approach to Targeting PCSK9
Charles A. German et al.
BIODRUGS (2020)
Plasma proteomics-based identification of novel biomarkers in early gastric cancer
Bin Zhou et al.
CLINICAL BIOCHEMISTRY (2020)
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer
James Yarmolinsky et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pseurotin A as a novel suppressor of hormone dependent breast cancer progression and recurrence by inhibiting PCSK9 secretion and interaction with LDL receptor
Khaldoun S. Abdelwahed et al.
PHARMACOLOGICAL RESEARCH (2020)
Identification of the Six-RNA-Binding Protein Signature for Prognosis Prediction in Bladder Cancer
Yucai Wu et al.
FRONTIERS IN GENETICS (2020)
PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
Silvano Fasolato et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer
Xinjian Liu et al.
NATURE (2020)
Effects of immunisation against PCSK9 in mice bearing melanoma
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2020)
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Binlu Huang et al.
NATURE METABOLISM (2020)
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Matthew J. Watt et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system
Amir Abbas Momtazi-Borojeni et al.
ATHEROSCLEROSIS (2019)
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study
Aldo Bonaventura et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Cholesterol and Its Metabolites in Tumor Growth: Therapeutic Potential of Statins in Cancer Treatment
Adele Chimento et al.
FRONTIERS IN ENDOCRINOLOGY (2019)
Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries
Toshiyuki Nishikido et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2019)
Potential anti-tumor effect of a nanoliposomal antiPCSK9 vaccine in mice bearing colorectal cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Effects of immunization against PCSK9 in an experimental model of breast cancer
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2019)
Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained
Paul Lebeau et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2018)
Role of metabolism in cancer cell radioresistance and radiosensitization methods
Le Tang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
PCSK9 induces a pro-inflammatory response in macrophages
Chiara Ricci et al.
SCIENTIFIC REPORTS (2018)
Validation of miRNA prognostic power in hepatocellular carcinoma using expression data of independent datasets
Adam Nagy et al.
SCIENTIFIC REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A Mendelian randomization study of the effects of blood lipids on breast cancer risk
Christoph Nowake et al.
NATURE COMMUNICATIONS (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting metastasis-initiating cells through the fatty acid receptor CD36
Gloria Pascual et al.
NATURE (2017)
A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition
Jian'an Bai et al.
ONCOTARGET (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Exogenous lipids promote the growth of breast cancer cells via CD36
Jing Zhao et al.
ONCOLOGY REPORTS (2017)
Inhibition of PCSK9 protects against radiation-induced damage of prostate cancer cells
Si-Shun Gan et al.
ONCOTARGETS AND THERAPY (2017)
PCSK9 regulates apoptosis in human lung adenocarcinoma A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways
Xiaohui Xu et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2017)
Actinidia chinensis Planch root extract inhibits cholesterol metabolism in hepatocellular carcinoma through upregulation of PCSK9
Mingyan He et al.
ONCOTARGET (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
Inhibitory effect of PCSK9 on Abca1 protein expression and cholesterol efflux in macrophages
Maria Pia Adorni et al.
ATHEROSCLEROSIS (2017)
PCSK9 inhibitors - from discovery of a single mutation to a groundbreaking therapy of lipid disorders in one decade
Krzysztof Jaworski et al.
ARCHIVES OF MEDICAL SCIENCE (2017)
New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway
Zhi-Han Tang et al.
ATHEROSCLEROSIS (2017)
LRP1 modulates the microglial immune response via regulation of JNK and NF-κB signaling pathways
Longyu Yang et al.
JOURNAL OF NEUROINFLAMMATION (2016)
Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015
Haidong Wang et al.
LANCET (2016)
LDL receptor-related protein-1 regulates NFκB and microRNA-155 in macrophages to control the inflammatory response
Elisabetta Mantuano et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Cholesterol activates the G-protein coupled receptor Smoothened to promote Hedgehog signaling
Giovanni Luchetti et al.
eLife (2016)
Lipid metabolic reprogramming in cancer cells
S. Beloribi-Djefaflia et al.
ONCOGENESIS (2016)
PCSK9 Induces CD36 Degradation and Affects Long-Chain Fatty Acid Uptake and Triglyceride Metabolism in Adipocytes and in Mouse Liver
Annie Demers et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2015)
Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study
David de Gonzalo-Calvo et al.
BMC CANCER (2015)
Decreased PCSK9 expression in human hepatocellular carcinoma
Mamatha Bhat et al.
BMC GASTROENTEROLOGY (2015)
Proprotein convertase subtilisin/kexin type 9 (PCSK9), soluble lectin-like oxidized LDL receptor 1 (sLOX-1) and ankle brachial index in patients with differentiated thyroid cancer
Cigdem Ozkan et al.
ENDOCRINE JOURNAL (2015)
Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9
Quoc-Tuan Le et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
Fabienne Guillaumond et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Elevated free fatty acid uptake via CD36 promotes epithelial-mesenchymal transition in hepatocellular carcinoma
Aritro Nath et al.
SCIENTIFIC REPORTS (2015)
Multivalent N-Acetylgalactosamine-Conjugated siRNA Localizes in Hepatocytes and Elicits Robust RNAi-Mediated Gene Silencing
Jayaprakash K. Nair et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2014)
Cholesterol selectively activates canonical Wnt signalling over non-canonical Wnt signalling
Ren Sheng et al.
NATURE COMMUNICATIONS (2014)
PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells
Emile Levy et al.
ATHEROSCLEROSIS (2013)
Low density receptor-related protein 1 (LRP1) promotes anti-inflammatory phenotype in murine macrophages
Petra May et al.
CELL AND TISSUE RESEARCH (2013)
POTENTIAL USE OF RECOMBINANT HUMAN THYROTROPIN IN THE TREATMENT OF DISTANT METASTASES IN PATIENTS WITH DIFFERENTIATED THYROID CANCER
Joanna Klubo-Gwiezdzinska et al.
ENDOCRINE PRACTICE (2013)
Cholesterol induces cardiac hypertrophy by activating the AKT pathway
Hyunjung Lee et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2013)
Alterations in Gene Expression of Proprotein Convertases in Human Lung Cancer Have a Limited Number of Scenarios
Ilya V. Demidyuk et al.
PLOS ONE (2013)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
Maryssa Canuel et al.
PLOS ONE (2013)
SILAC-based quantitative proteomic analysis of gastric cancer secretome
Arivusudar Marimuthu et al.
PROTEOMICS CLINICAL APPLICATIONS (2013)
Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia
Marianne Abifadel et al.
ATHEROSCLEROSIS (2012)
PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling
Kai Kysenius et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2012)
PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-κB activation in THP-1-derived macrophages
Zhihan Tang et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2012)
Regulation of Epithelial Sodium Channel Trafficking by Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)
Vikas Sharotri et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver
Xiaowei Sun et al.
NEOPLASIA (2012)
Tumor Microenvironment-Derived Proteins Dominate the Plasma Proteome Response during Breast Cancer Induction and Progression
Sharon J. Pitteri et al.
CANCER RESEARCH (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Low-Density Lipoprotein Cholesterol and the Risk of Cancer: A Mendelian Randomization Study
Marianne Benn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Lipid droplets in inflammation and cancer
Patricia T. Bozza et al.
PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS (2010)
Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172 210 men and women: a prospective 19-year follow-up study
A. M. Strasak et al.
ANNALS OF ONCOLOGY (2009)
PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1
Mary Cabell Jonas et al.
EMBO REPORTS (2008)
Proprotein convertase Subtilisin/Kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration
Ahmed Zaid et al.
HEPATOLOGY (2008)
LDL receptor-related protein 1: Unique tissue-specific functions revealed by selective gene knockout studies
Anna P. Lillis et al.
PHYSIOLOGICAL REVIEWS (2008)
The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2
Steve Poirier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence
Aaron R. Folsom et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
The self-inhibited structure of full-length PCSK9 at 1.9 Å reveals structural homology with resistin within the C-terminal domain
Eric N. Hampton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
The proprotein convertases are potential targets in the treatment of dyslipidemia
Nabil G. Seidah et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat a of low density lipoprotein receptor decreases receptor recycling and increases degradation
Da-Wei Zhang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol
Derek E. Piper et al.
STRUCTURE (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
NARC-1/PCSK9 and its natural mutants -: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol
S Benjannet et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma
JI Botella-Carretero et al.
ENDOCRINE-RELATED CANCER (2004)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1):: Liver regeneration and neuronal differentiation
NG Seidah et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Share Paper
